5th International Conference on

HIV/AIDS, STDs and STIs

November 13-14, 2017 Las Vegas, Nevada, USA

Drug resistance mutations in human immunodeficiency virus type 2 (HIV-2) strains from patients in Ghana

Christopher Z Abana¹, Kwamena W C Sagoe¹, Evelyn Y Bonney¹, Edward K Maina^{1,2}, Ishmael D Aziati¹, Esinam Agbosu¹, Gifty Mawuli¹, Linda M Styer³, James A M Brandful¹ and William K Ampofo¹

¹University of Ghana, Ghana ²Kenya Medical Research Institute, Kenya ³Bloodborne Viruses Laboratory, USA

Statement of the Problem: Antiretroviral therapy (ART) and drug resistance studies worldwide have focused almost exclusively on HIV-1. In Ghana, the HIV epidemic is characterized by the domination of HIV-1 with few HIV-2 co-circulating. As a result, there is limited information on ART and drug resistance in HIV-2 patients. We therefore sought to determine viral load and drug resistance mutations in HIV-2 patients in Ghana to inform the clinical management of such individuals.

Methods: We used purposive sampling to collect blood from 16 consented patients confirmed as HIV-2 and HIV-1/2 dual infections by serology. A real-time RT-PCR assay was used to determine the viral load of patients by using an HIV-2 RNA standard as a reference. Nucleic acid (RNA and DNA) were extracted from plasma and peripheral blood mononuclear cells (PBMC) respectively. The reverse transcriptase (RT) and protease (PR) genes of HIV-2 were amplified, sequenced and then analyzed for drug resistance mutations and HIV-2 group.

Findings: Nine patients comprising 7 ART-naïve and 2 ART-experienced had detectable HIV-2 viral loads (range: 2.35–5.45 logIU/ mL). Five of the patients were identified as HIV-2 group B and two as HIV-2 group A. HIV-2 drug resistance mutations (M184V, K65R, Y115F) were identified in one ART-experienced patient.

Conclusion & Significance: This is the first report of HIV-2 viral load determination and drug resistance mutations in HIV-2 strains in patients in Ghana. The results indicate the need for continuous monitoring of HIV-2 drug resistance to improve clinical management of HIV-2 infected patients in a setting focused on HIV-1 patients.

cabana@noguchi.ug.edu.gh